Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies
The unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality papers describing clinical trials of different vacc...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2021.1971569 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850137766181994496 |
|---|---|
| author | Liubov I. Kozlovskaya Anastasia N. Piniaeva Georgy M. Ignatyev Ilya V. Gordeychuk Viktor P. Volok Yulia V. Rogova Anna A. Shishova Anastasia A. Kovpak Yury Yu. Ivin Liliya P. Antonova Kirill M. Mefyod Lyubov S. Prokosheva Anna S. Sibirkina Yuliya Yu. Tarasova Ekaterina O. Bayurova Olga S. Gancharova Victoria V. Illarionova Grigory S. Glukhov Olga S. Sokolova Konstantin V. Shaitan Anastasia M. Moysenovich Stanislav A. Gulyaev Tatiana V. Gulyaeva Andrey V. Moroz Larissa V. Gmyl Elena G. Ipatova Mikhail P. Kirpichnikov Alexey M. Egorov Aleksandra A. Siniugina Aydar A. Ishmukhametov |
| author_facet | Liubov I. Kozlovskaya Anastasia N. Piniaeva Georgy M. Ignatyev Ilya V. Gordeychuk Viktor P. Volok Yulia V. Rogova Anna A. Shishova Anastasia A. Kovpak Yury Yu. Ivin Liliya P. Antonova Kirill M. Mefyod Lyubov S. Prokosheva Anna S. Sibirkina Yuliya Yu. Tarasova Ekaterina O. Bayurova Olga S. Gancharova Victoria V. Illarionova Grigory S. Glukhov Olga S. Sokolova Konstantin V. Shaitan Anastasia M. Moysenovich Stanislav A. Gulyaev Tatiana V. Gulyaeva Andrey V. Moroz Larissa V. Gmyl Elena G. Ipatova Mikhail P. Kirpichnikov Alexey M. Egorov Aleksandra A. Siniugina Aydar A. Ishmukhametov |
| author_sort | Liubov I. Kozlovskaya |
| collection | DOAJ |
| description | The unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality papers describing clinical trials of different vaccine products, basic detailed data on general toxicity, reproductive toxicity, immunogenicity, protective efficacy and durability of immune response in animal models are scarce. Here, we developed a β-propiolactone-inactivated whole virion vaccine CoviVac and assessed its safety, protective efficacy, immunogenicity and stability of the immune response in rodents and non-human primates. The vaccine showed no signs of acute/chronic, reproductive, embryo- and fetotoxicity, or teratogenic effects, as well as no allergenic properties in studied animal species. The vaccine induced stable and robust humoral immune response both in form of specific anti-SARS-CoV-2 IgG and NAbs in mice, Syrian hamsters, and common marmosets. The NAb levels did not decrease significantly over the course of one year. The course of two immunizations protected Syrian hamsters from severe pneumonia upon intranasal challenge with the live virus. Robustness of the vaccine manufacturing process was demonstrated as well. These data encouraged further evaluation of CoviVac in clinical trials. |
| format | Article |
| id | doaj-art-25dd68ffe74e41b1a33bb195f5965272 |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-25dd68ffe74e41b1a33bb195f59652722025-08-20T02:30:45ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512021-01-011011790180610.1080/22221751.2021.1971569Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studiesLiubov I. Kozlovskaya0Anastasia N. Piniaeva1Georgy M. Ignatyev2Ilya V. Gordeychuk3Viktor P. Volok4Yulia V. Rogova5Anna A. Shishova6Anastasia A. Kovpak7Yury Yu. Ivin8Liliya P. Antonova9Kirill M. Mefyod10Lyubov S. Prokosheva11Anna S. Sibirkina12Yuliya Yu. Tarasova13Ekaterina O. Bayurova14Olga S. Gancharova15Victoria V. Illarionova16Grigory S. Glukhov17Olga S. Sokolova18Konstantin V. Shaitan19Anastasia M. Moysenovich20Stanislav A. Gulyaev21Tatiana V. Gulyaeva22Andrey V. Moroz23Larissa V. Gmyl24Elena G. Ipatova25Mikhail P. Kirpichnikov26Alexey M. Egorov27Aleksandra A. Siniugina28Aydar A. Ishmukhametov29Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaDepartment of Biology, Lomonosov Moscow State University, Moscow, RussiaDepartment of Biology, Lomonosov Moscow State University, Moscow, RussiaDepartment of Biology, Lomonosov Moscow State University, Moscow, RussiaDepartment of Biology, Lomonosov Moscow State University, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaDepartment of Biology, Lomonosov Moscow State University, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaChumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products of Russian Academy of Sciences, Moscow, RussiaThe unprecedented in recent history global COVID-19 pandemic urged the implementation of all existing vaccine platforms to ensure the availability of the vaccines against COVID-19 to every country in the world. Despite the multitude of high-quality papers describing clinical trials of different vaccine products, basic detailed data on general toxicity, reproductive toxicity, immunogenicity, protective efficacy and durability of immune response in animal models are scarce. Here, we developed a β-propiolactone-inactivated whole virion vaccine CoviVac and assessed its safety, protective efficacy, immunogenicity and stability of the immune response in rodents and non-human primates. The vaccine showed no signs of acute/chronic, reproductive, embryo- and fetotoxicity, or teratogenic effects, as well as no allergenic properties in studied animal species. The vaccine induced stable and robust humoral immune response both in form of specific anti-SARS-CoV-2 IgG and NAbs in mice, Syrian hamsters, and common marmosets. The NAb levels did not decrease significantly over the course of one year. The course of two immunizations protected Syrian hamsters from severe pneumonia upon intranasal challenge with the live virus. Robustness of the vaccine manufacturing process was demonstrated as well. These data encouraged further evaluation of CoviVac in clinical trials.https://www.tandfonline.com/doi/10.1080/22221751.2021.1971569VaccineSARS-CoV-2COVID-19neutralizing antibodiessafetyimmunogenicity |
| spellingShingle | Liubov I. Kozlovskaya Anastasia N. Piniaeva Georgy M. Ignatyev Ilya V. Gordeychuk Viktor P. Volok Yulia V. Rogova Anna A. Shishova Anastasia A. Kovpak Yury Yu. Ivin Liliya P. Antonova Kirill M. Mefyod Lyubov S. Prokosheva Anna S. Sibirkina Yuliya Yu. Tarasova Ekaterina O. Bayurova Olga S. Gancharova Victoria V. Illarionova Grigory S. Glukhov Olga S. Sokolova Konstantin V. Shaitan Anastasia M. Moysenovich Stanislav A. Gulyaev Tatiana V. Gulyaeva Andrey V. Moroz Larissa V. Gmyl Elena G. Ipatova Mikhail P. Kirpichnikov Alexey M. Egorov Aleksandra A. Siniugina Aydar A. Ishmukhametov Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies Emerging Microbes and Infections Vaccine SARS-CoV-2 COVID-19 neutralizing antibodies safety immunogenicity |
| title | Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies |
| title_full | Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies |
| title_fullStr | Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies |
| title_full_unstemmed | Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies |
| title_short | Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies |
| title_sort | long term humoral immunogenicity safety and protective efficacy of inactivated vaccine against covid 19 covivac in preclinical studies |
| topic | Vaccine SARS-CoV-2 COVID-19 neutralizing antibodies safety immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2021.1971569 |
| work_keys_str_mv | AT liubovikozlovskaya longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT anastasianpiniaeva longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT georgymignatyev longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT ilyavgordeychuk longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT viktorpvolok longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT yuliavrogova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT annaashishova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT anastasiaakovpak longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT yuryyuivin longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT liliyapantonova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT kirillmmefyod longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT lyubovsprokosheva longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT annassibirkina longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT yuliyayutarasova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT ekaterinaobayurova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT olgasgancharova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT victoriavillarionova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT grigorysglukhov longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT olgassokolova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT konstantinvshaitan longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT anastasiammoysenovich longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT stanislavagulyaev longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT tatianavgulyaeva longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT andreyvmoroz longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT larissavgmyl longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT elenagipatova longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT mikhailpkirpichnikov longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT alexeymegorov longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT aleksandraasiniugina longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies AT aydaraishmukhametov longtermhumoralimmunogenicitysafetyandprotectiveefficacyofinactivatedvaccineagainstcovid19covivacinpreclinicalstudies |